Physician profile
Emad N Gobran
NPI 1376964023
$3,462.17
in general payments reported to CMS, 2019-2025
29 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $68.46 · 2021: $213 · 2022: $544 · 2023: $807 · 2024: $766 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.09 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.52 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $407.67 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $372.21 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $237.61 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $226.98 | 2022-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $182.53 | 2021-2023 | Acthar |
| Davol INC. | $150.00 | 2025 | Phasix Mesh |
| Lilly USA, LLC | $141.16 | 2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $128.51 | 2020-2022 | |
| Becton, Dickinson and Company | $124.23 | 2024 | Bard 3dmax Mesh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.27 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $103.42 | 2022-2025 | Jynarque |
| Scpharmaceuticals INC. | $79.24 | 2025 | |
| Amgen INC. | $77.68 | 2024-2025 | Krystexxa, Uplizna |
| Horizon Therapeutics Plc | $73.37 | 2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $71.13 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $58.47 | 2023-2025 | Benlysta, Jesduvroq, Shingrix |
| Novartis Pharmaceuticals Corporation | $54.74 | 2019-2021 | |
| Pfizer INC. | $53.32 | 2019-2023 | |
| Allergan, INC. | $42.95 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $31.65 | 2021 | |
| Vifor Pharma, INC. | $30.39 | 2023 | Korsuva, Veltassa |
| Akebia Therapeutics INC | $27.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.55 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.04 | 2019 | |
| Chiesi USA, INC. | $15.76 | 2025 | Cleviprex |
| Exact Sciences Corporation | $14.81 | 2025 | Cologuard Collection Kit |
| Calliditas Therapeutics US INC. | $14.58 | 2025 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Gobran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.